1. Home
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By End-use And Segment Forecasts, 2022 - 2030

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By End-use And Segment Forecasts, 2022 - 2030

  • October 2022
  • 150 pages
  • ID: 6360883
  • Format: PDF
  • Grand View Research


Table of Contents

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Immunomodulators), By Application, By Distribution Channel, By End-use, And Segment Forecasts, 2022 - 2030

Cancer Immunotherapy Market Growth & Trends

The global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030, registering CAGR of 7.2% during the forecast period. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.

Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market.For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy.

Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.

Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy.Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment.

Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.

The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others.Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery.

Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years.The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies.

For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.

Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.

Cancer Immunotherapy Market Report Highlights
• Monoclonal antibodies segment held the largest market share in 2021 owing to rising investments in the R&D of monoclonal antibodies
• By product, the oncolytic viral therapies &cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
• Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
• The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
• The hospitals & clinics segment led the market in 2021 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
• Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
• Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035

  • $ 5899
  • January 2023
  • 315 pages

INTRODUCTION Over the years, various studies have validated the successful use of tumor-infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous ...

  • World
  • APAC
  • Cancer
  • Immunotherapy
  • Industry analysis


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on